TCGA-A2-A3KC-01A-11R-A213-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 37
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.550
- WNT_BETA_CATENIN_SIGNALING+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- UV_RESPONSE_DN+0.390
- MYOGENESIS+0.370
- ANGIOGENESIS+0.360
- APICAL_JUNCTION+0.330
- APICAL_SURFACE+0.310
- HEDGEHOG_SIGNALING+0.280
- MITOTIC_SPINDLE+0.280
Top 10 suppressed
- MYC_TARGETS_V1-0.550
- OXIDATIVE_PHOSPHORYLATION-0.550
- MTORC1_SIGNALING-0.540
- MYC_TARGETS_V2-0.440
- E2F_TARGETS-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.420
- GLYCOLYSIS-0.370
- FATTY_ACID_METABOLISM-0.330
- INTERFERON_ALPHA_RESPONSE-0.330
- G2M_CHECKPOINT-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.898 |
| 2 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.895 |
| 3 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.891 |
| 4 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.886 |
| 5 | 20050037.TNBC | — | C | 0.885 |
| 6 | SRR8613732 | — | A | 0.884 |
| 7 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.882 |
| 8 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.873 |
| 9 | R116 | — | — | 0.868 |
| 10 | TCGA-CR-6488-01A-12R-2081-07 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.550 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.510 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.120 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |